Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7664-7673

  Bravo, Susana B ^a   García Rendueles, María E R ^a   Seoane, Rafael ^a   Dosil, Vanesa ^a   Cameselle Teijeiro, José ^b   López Lázaro, Luis ^c   Zalvide, Juan ^a   Barreiro, Francisco ^b   Pombo, Celia M ^a   Álvarez, Clara V ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; DEHYDRODIDEMNIN B; HISTONE H3; PLITIDEPSIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MITOSIS; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; UNDIFFERENTIATED CARCINOMA;

ADULT; AGAR; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HELA CELLS; HISTONES; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; MODELS, STATISTICAL; THYROID GLAND; THYROID NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27744526843     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0455     Document Type: Article

References (57)

1. Ordonez N, Baloch Z, Matias-Guiu X, et al. Part 2: Tumours of the thyroid and parathyroid: undifferentiated (anaplastic) carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng E, editors. Pathology and genetics of tumours of endocrine organs. IARC/WHO classification of tumours. Lyon:; 2004. p. 77-80.
2. Schlumberger JM. Anaplastic thyroid carcinoma [homepage on the Internet], Orphanet Rare diseases: S. Filletti. 2004 March 2004.
3. Giuffrida D, Gharib H. Cardiac metastasis from primary anaplastic thyroid carcinoma: report of three cases and a review of the literature. Endocr Relat Cancer 2001 Mar;8:71-3.
4. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: Current diagnosis and treatment. Ann Oncol 2000 Sep;11:1083-9.
5. Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999 Nov;84:4043-9.
6. Ain KB. Anaplastic thyroid carcinoma: Behavior, biology, and therapeutic approaches. Thyroid 1998 Aug;8:715-26.
7. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion, collaborative anaplastic thyroid cancer health intervention trials (CATCHIT) group. Thyroid 2000 Jul;10:587-94.
8. Veness MJ, Porter GS, Morgan GJ. Anaplastic thyroid carcinoma: Dismal outcome despite current treatment approach. ANZ J Surg 2004 Jul;74:559-62.
9. Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: Three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002 Jun 17;86:1848-53.
10. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery 2001 Dec;130:1028-34.
11. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001 May 18;84:1424-31.
12. Schmied BM, Ulrich AB, Matsuzaki H, et al. Biologic instability of pancreatic cancer xenografts in the nude mouse. Carcinogenesis 2000 Jun;21:1121-7.
13. Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res 2002 Jan;8:293-8.
14. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998-1999;17:279-84.
15. Schiff BA, McMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 2004 Dec 15;10:8594-602.
16. Voigt W, Bulankin A, Muller T, et al. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 2000 May;6:2087-93.
17. Kitazono M, Robey R, Zhan Z, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the na(+)/I(-) symporterand iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001 Jul;86:3430-5.
18. Furuya F, Shimura H, Suzuki H, et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004 Jun;145:2865-75.
19. Wang CY, Zhong WB, Chang TC, Lai SM, Tsai YF. Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2003 Jul;88:3021-6.
20. Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002 Dec;12:1063-70.
21. Portella G, Scala S, Vitagliano D, Vecchio G, Fusco A. ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 2002 Jun;87:2525-31.
22. Pan J, Xu G, Yeung SC. Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin Endocrinol Metab 2001 Oct;86:4731-40.
23. Dziba JM, Ain KB. Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. J Clin Endocrinol Metab 2004 May;89:2127-35.
24. Mitsiades CS, Sykoutri D, McMullan C, Poulaki V, Mitsiades N. Effect of imatinib mesylate (gleevec) on anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 2003 Oct;88:5043,4; author reply 5044.
25. Podtcheko A, Ohtsuru A, Tsuda S, et al. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003 Apr;88:1889-96.
26. Jimeno J, Lopez-Martin JA, Ruiz-Casado A, Izquierdo MA, Scheuer PJ, Rinehart K. Progress in the clinical development of new marine-derived anti-cancer compounds. Anticancer Drugs 2004 Apr;15:321-9.
27. Cardenas F, Caba JM, Feliz M, Lloyd-Williams P, Giralt E. Analysis of conformational equilibria in Aplidin using selective excitation 2D NMR spectroscopy and molecular mechanics/dynamics calculations. J Org Chem 2003 Dec 12;68:9554-62.
28. Bresters D, Broekhuizen AJ, Kaaijk P, Faircloth GT, Jimeno J, Kaspers GJ. In vitro cytotoxicity of Aplidin and cross-resistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development. Leukemia 2003 Jul;17:1338-43.
29. Erba E, Serafini M, Gaipa G, et al. Effect of Aplidin in acute lymphoblastic leukaemia cells. Br J Cancer 2003 Aug 18;89:763-73.
30. Gajate C, An F, Mollinedo F. Rapid and selective apoptosis in human leukemic cells induced by Aplidin through a Fas/CD95- and mitochondrial-mediated mechanism. Clin Cancer Res 2003 Apr;9:1535-45.
31. Erba E, Bassano L, Di Liberti G, et al. Cell cycle phase perturbations and apoptosis in tumour cells induced by Aplidin. Br J Cancer 2002 May 6;86:1510-7.
32. Cuadrado A, Garcia-Fernandez LF, Gonzalez L, et al. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, src, JNK, p38 MAPK. J Biol Chem 2003 Jan 3;278:241-50.
33. Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992 Mar 1;52:1369-71.
34. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993 Jan;91:179-84.
35. Bravo SB, Pampin S, Cameselle-Teijeiro J, et al. TGF-β-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-κB activation. Oncogene 2003 Oct 30;22:7819-30.
36. Ito T, Seyama T, Hayashi Y, et al. Establishment of two human thyroid carcinoma cell lines (8305C, 8505C) bearing p53 gene mutations. Int J Oncology 1994;4:583-6.
37. Carneiro C, Alvarez CV, Zalvide J, Vidal A, Dominguez F. TGF-β1 actions on FRTL-5 cells provide a model for the physiological regulation of thyroid growth. Oncogene 1998 Mar;16:1455-65.
38. Garcia A, Alvarez CV, Smith RG, Dieguez C. Regulation of pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor. Mol Endocrinol 2001 Sep;15:1484-95.
39. Gomez SG, Bueren JA, Faircloth GT, Jimeno J, Albella B. In vitro toxicity of three new antitumoral drugs (trabectedin, Aplidin, and kahalalide F) on hematopoietic progenitors and stem cells. Exp Hematol 2003 Nov;31:1104-11.
40. Cuadrado A, Gonzalez L, Suarez Y, Martinez T, Munoz A. JNK activation is critical for Aplidin-induced apoptosis. Oncogene 2004 Jun 10;23:4673-80.
41. Garcia-Fernandez LF, Losada A, Alcaide V, et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C δ. Oncogene 2002 Oct 24;21:7533-44.
42. Celli N, Mariani B, Di Carlo F, et al. Determination of Aplidin, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection. J Pharm Biomed Anal 2004 Feb 18;34:619-30.
43. Mitsiades CS, Poulaki V, McMullan C, et al. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 2005 May 15;11:3958-65.
44. Rosato RR, Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2003 Jan-Feb;2:30-7.
45. Kang J, Chen J, Shi Y, Jia J, Zhang Y. Curcumin-induced histone hypoacetylation: The role of reactive oxygen species. Biochem Pharmacol 2005 Apr 15;69:1205-13.
46. Balasubramanyam K, Altaf M, Varier RA, et al. Poly-isoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 2004 Aug 6;279:33716-26.
47. Taddei A, Roche D, Bickmore WA, Almouzni G. The effects of histone deacetylase inhibitors on heterochromatin: Implications for anticancer therapy? EMBO Rep 2005 Jun;6:520-4.
48. Papotti M, Volante M, Negro F, Eusebi V, Bussolati G. Thyroglobulin mRNA expression helps to distinguish anaplastic carcinoma from angiosarcoma of the thyroid. Virchows Arch 2000 Dec;437:635-42.
49. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993 Sep 24;74:957-67.
50. Schmitt CA, Lowe SW. Apoptosis and chemoresistance in transgenic cancer models. J Mol Med 2002 Mar;80:137-46.
51. Bearss DJ, Subler MA, Hundley JE, Troyer DA, Salinas RA, Windle JJ. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors. Oncogene 2000 Feb 21;19:1114-22.
52. Soh JW, Weinstein IB. Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. J Biol Chem 2003 Sep 5;278:34709-16.
53. Malumbres M, Carnero A. Cell cycle deregulation: A common motif in cancer. Prog Cell Cycle Res 2003;5:5-18.
54. Coleman ML, Marshall CJ, Olson MF. Ras promotes p21 (Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J 2003 May 1;22:2036-46.
55. Fagin JA. How thyroid tumors start and why it matters: Kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004 Nov;183:249-56.
56. Borrow J, Stanton VP, Jr., Andresen JM, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996 Sep;14:33-41.
57. Yang XJ. The diverse superfamily of lysine acetyltransferases and their rates in leukemia and other diseases. Nucleic Acids Res 2004 Feb 11;32:959-76.